Neogenomics Inc.
NEO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.09B
Close$
$-11.19
169.9% downside
Current Fair Value
169.9% downsideOvervalued by 169.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.09 Billion |
|---|---|
| Enterprise Value | $2.40 Billion |
| Earnings per Share | $-0.84 |
| Beta | 1.83 |
| Outstanding Shares | 128,587,000 |
Return
| Return on Equity | -4.03% |
|---|---|
| Return on Assets | -2.35% |
| Return on Invested Capital | -2.56% |
Valuation & Multiples
| P/E Ratio | -64.91 |
|---|---|
| PEG | 89.92 |
| Price to Sales | 2.67 |
| Price to Book Ratio | 2.67 |
| Enterprise Value to Revenue | 3.04 |
| Enterprise Value to EBIT | -74.26 |
| Enterprise Value to Net Income | -75 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS
$0.07
Est. $0.06Revenue
$209.25 M
Est. $206.70 MNext Earnings Call
Expected Date
February 16, 2027
EPS Estimate
$0.07
Consensus analyst estimateRevenue Estimate
$210.60 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 0.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 5,200▼ 90.32% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.56%▼ 516.44% |
|---|---|
| Total Invested | $264.71M▼ 87.57% |
| Investors Holding | 116▼ 162.00% |
About Neogenomics Inc.
1,600 employees
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...